Last reviewed · How we verify

Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers

NCT00734240 Phase 1 COMPLETED

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 from the blood, and to evaluate the effectiveness of ISIS 353512 in lowering a protein in the blood associated with inflammation.

Details

Lead sponsorIonis Pharmaceuticals, Inc.
PhasePhase 1
StatusCOMPLETED
Enrolment103
Start date2008-07
Completion2010-03

Conditions

Interventions

Primary outcomes

Countries

Canada